Overview of Dr. Shafique
Dr. Michael Shafique is an oncologist in Tampa, FL and is affiliated with H. Lee Moffitt Cancer Center and Research Institute. He received his medical degree from University of Virginia School of Medicine and has been in practice 6 years. He is one of 173 doctors at H. Lee Moffitt Cancer Center and Research Institute who specialize in Oncology. He has more than 10 publications and over 500 citings.
Office
12902 Usf Magnolia Dr
Tampa, FL 33612
Education & Training
University of South Florida MorsaniFellowship, Hematology and Medical Oncology, 2017
Duke University HospitalResidency, Internal Medicine, 2011 - 2014
University of Virginia School of MedicineClass of 2011
Certifications & Licensure
FL State Medical License 2014 - 2026
NC State Medical License 2011 - 2014- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Inductee Alpha Omega Alpha Honor Medical Society, 2011
Clinical Trials
- Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Previously Been Treated With Immunotherapy Start of enrollment: 2020 Apr 16
- Immune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLC Start of enrollment: 2020 Nov 23
- Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery Start of enrollment: 2015 Oct 21
Roles: Principal Investigator, Contact
Publications & Presentations
PubMed
- 2 citationsOsimertinibafatinib as first-line treatment for patients with metastatic non-small cell lung cancer with anexon 19 deletion or exon 21 L858R mutation.Sophia Gilardone, Ram Thapa, José Laborde, Michael Shafique, Michael Shafique
Journal of Thoracic Disease. 2023-11-30 - 2 citationsA phase I/IB trial of binimetinib in combination with erlotinib in NSCLC harboring activating KRAS or EGFR mutations.Andreas N Saltos, Ben C Creelan, Tawee Tanvetyanon, Alberto A Chiappori, Scott J Antonia
Lung Cancer. 2023-09-01 - 5 citationsDose-Limiting Pulmonary Toxicity in a Phase 1/2 Study of Radiation and Chemotherapy with Ipilimumab Followed by Nivolumab for Patients With Stage 3 Unresectable Non-Sm...Casey L Liveringhouse, Kujtim Latifi, Amalin G Asous, Nghi B Lam, Stephen A Rosenberg
International Journal of Radiation Oncology, Biology, Physics. 2023-07-15
Press Mentions
Vaccinex Announces Three Oral Presentations Highlighting Semaphorin 4D (SEMA4D) at the ASCO-SITC Clinical Immuno-Oncology SymposiumFebruary 6th, 2020
Strange Signs: Cancer-Related Paraneoplastic SyndromesNovember 15th, 2019
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
